Area of research
Oncology · Molecular Biology · cancer
Research interest
es Results Published Research Inventions Network Research Institutions Our academic collaborators’ seminal contributions push the field forward Directory Our constellation of renowned thinkers and partners Strategic Partnerships The right collaborators across pharma, biotech and nonprofit Early Career Researcher
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics
Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.
The Next Chapter of Cancer Immunology Research.
Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.
Abstract LB-B005: No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404
Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.
DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results.
Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B.
Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma
Basic rules to respond to PD-1 blockade cancer immunotherapy.
Intentional heterogeneity in autologous cell-based gene therapies: strategic considerations for first-in-human trials.
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.
Neoadjuvant PD-1 blockade: a new treatment option for patients with early-stage mismatch repair deficient solid tumors.
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
Supplementary Figure S4 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Supplementary Figure S1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A
David Baltimore (1938–2025)
Supplementary Figure S5 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
Data from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B